메뉴 건너뛰기




Volumn 6, Issue 10, 2016, Pages

Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; DOMPERIDONE; DOPAMINE 2 RECEPTOR; DRD2 PROTEIN, HUMAN; NEUROLEPTIC AGENT;

EID: 85017147317     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/TP.2016.195     Document Type: Article
Times cited : (129)

References (30)
  • 1
    • 84870057403 scopus 로고    scopus 로고
    • Pharmaco¬logical treatment of schizophrenia: A critical review of the pharmacology and clinical effects of current and future therapeutic agents
    • Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA. Pharmaco¬logical treatment of schizophrenia: A critical review of the pharmacology and clinical effects of current and future therapeutic agents. Mol Psychiatry 2012; 17: 1206-1227.
    • (2012) Mol Psychiatry , vol.17 , pp. 1206-1227
    • Miyamoto, S.1    Miyake, N.2    Jarskog, L.F.3    Fleischhacker, W.W.4    Lieberman, J.A.5
  • 2
  • 4
    • 0010686493 scopus 로고
    • Wong K. Brain receptors for antipsychotic drugs and dopamine: Direct binding assays
    • Seeman P, Chau-Wong M, Tedesco J, Wong K. Brain receptors for antipsychotic drugs and dopamine: Direct binding assays. Proc Natl Acad Sci USA 1975; 72: 4376-4380.
    • (1975) Proc Natl Acad Sci USA , vol.72 , pp. 4376-4380
    • Seeman, P.1    Chau-Wong, M.2    Tedesco, J.3
  • 5
    • 79952642829 scopus 로고    scopus 로고
    • All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2High receptors
    • Seeman P. All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2High receptors. CNS Neurosci Ther 2011; 17: 118-132.
    • (2011) CNS Neurosci Ther , vol.17 , pp. 118-132
    • Seeman, P.1
  • 6
    • 33645029075 scopus 로고    scopus 로고
    • Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice
    • Long LE, Malone DT, Taylor DA. Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology 2006; 31: 795-803.
    • (2006) Neuropsychopharmacology , vol.31 , pp. 795-803
    • Long, L.E.1    Malone, D.T.2    Taylor, D.A.3
  • 8
    • 84868122317 scopus 로고    scopus 로고
    • Multiple mechanisms involved in the large-spectrum therapeutic potential of canna-bidiol in psychiatric disorders
    • Campos AC, Moreira FA, Gomes FV, Del Bel EA, Guimaraes FS. Multiple mechanisms involved in the large-spectrum therapeutic potential of canna-bidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci 2012; 367: 3364-3378.
    • (2012) Philos Trans R Soc Lond B Biol Sci , vol.367 , pp. 3364-3378
    • Campos, A.C.1    Moreira, F.A.2    Gomes, F.V.3    Del Bel, E.A.4    Guimaraes, F.S.5
  • 9
    • 38349158960 scopus 로고    scopus 로고
    • The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin
    • Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 2008; 153: 199-215.
    • (2008) Br J Pharmacol , vol.153 , pp. 199-215
    • Pertwee, R.G.1
  • 10
    • 0021258595 scopus 로고
    • Dopamine receptor parameters detected by [3H]spiperone depend on tissue concentration: Analysis and exam¬ples
    • Seeman P, Ulpian C, Wreggett KA, Wells JW. Dopamine receptor parameters detected by [3H]spiperone depend on tissue concentration: Analysis and exam¬ples. J Neurochem 1984; 43: 221-235.
    • (1984) J Neurochem , vol.43 , pp. 221-235
    • Seeman, P.1    Ulpian, C.2    Wreggett, K.A.3    Wells, J.W.4
  • 11
    • 0015861774 scopus 로고
    • Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction
    • Cheng Y, Prusoff WH. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 per cent inhibition (IC50) of an enzymatic reaction. Biochem Pharmacol 1973; 22: 3099-3108.
    • (1973) Biochem Pharmacol , vol.22 , pp. 3099-3108
    • Cheng, Y.1    Prusoff, W.H.2
  • 12
    • 56549092215 scopus 로고    scopus 로고
    • Dopamine D2High receptors moderately elevated by bifeprunox and aripiprazole
    • Seeman P. Dopamine D2High receptors moderately elevated by bifeprunox and aripiprazole. Synapse 2008; 62: 902-908.
    • (2008) Synapse , vol.62 , pp. 902-908
    • Seeman, P.1
  • 13
    • 0002688012 scopus 로고    scopus 로고
    • Olanzapine binding to dopamine receptors in vitro and in vivoln
    • Tran PV, Bymaster F, Tye N, Herrera J, Breier A, Tollefson G (eds), Eli Lilly, Lippincott Williams & Wilk¬ins: Philadelphia, PA, USA
    • Seeman P, Kapur S. Olanzapine binding to dopamine receptors in vitro and in vivoln: Tran PV, Bymaster F, Tye N, Herrera J, Breier A, Tollefson G (eds). Olanzapine (Zyprexa)—A Novel Antipsychotic. Eli Lilly, Lippincott Williams & Wilk¬ins: Philadelphia, PA, USA, 2000, 3-24.
    • (2000) Olanzapine (Zyprexa)—A Novel Antipsychotic , pp. 3-24
    • Seeman, P.1    Kapur, S.2
  • 14
    • 0043269348 scopus 로고    scopus 로고
    • Dopamine displaces [3H]domperidone from high- affinity sites of the dopamine D2 receptor, but not [3H]raclopride or [3H]spiperone in isotonic medium
    • Seeman P, Tallerico T, Ko F. Dopamine displaces [3H]domperidone from high- affinity sites of the dopamine D2 receptor, but not [3H]raclopride or [3H]spiperone in isotonic medium: Implications for human positron emission tomography. Synapse 2003; 49: 209-215.
    • (2003) Implications for Human Positron Emission Tomography. Synapse , vol.49 , pp. 209-215
    • Seeman, P.1    Tallerico, T.2    Ko, F.3
  • 15
    • 67650410021 scopus 로고    scopus 로고
    • Dopamine D2High receptors stimulated by phencyclidines, LSD, salvinorin A, and modafinil
    • Seeman P, Guan H-C, Hirbec H. Dopamine D2High receptors stimulated by phencyclidines, LSD, salvinorin A, and modafinil. Synapse 2009; 63: 698-704.
    • (2009) Synapse , vol.63 , pp. 698-704
    • Seeman, P.1    Guan, H.-C.2    Hirbec, H.3
  • 16
    • 37249075040 scopus 로고    scopus 로고
    • Anti-Parkinson therapeutic potencies correlate with their affinities for dopamine D2High receptors
    • Seeman P. Anti-Parkinson therapeutic potencies correlate with their affinities for dopamine D2High receptors. Synapse 2007; 61: 1013-1018.
    • (2007) Synapse , vol.61 , pp. 1013-1018
    • Seeman, P.1
  • 17
    • 0025876938 scopus 로고
    • Effects of cannabidiol in animal models predictive of antipsychotic activity
    • Zuardi AW, Rodrigues JA, Cunha JM. Effects of cannabidiol in animal models predictive of antipsychotic activity. Psychopharmacology (Berl) 1991; 104: 260-264.
    • (1991) Psychopharmacology (Berl) , vol.104 , pp. 260-264
    • Zuardi, A.W.1    Rodrigues, J.A.2    Cunha, J.M.3
  • 18
    • 17444393586 scopus 로고    scopus 로고
    • Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice
    • Moreira FA, Guimaraes FS. Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice. Eur J Pharmacol 2005; 512: 199-205.
    • (2005) Eur J Pharmacol , vol.512 , pp. 199-205
    • Moreira, F.A.1    Guimaraes, F.S.2
  • 19
    • 2442641276 scopus 로고    scopus 로고
    • Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum
    • Guimaraes VM, Zuardi AW, Del Bel EA, Guimaraes FS. Cannabidiol increases Fos expression in the nucleus accumbens but not in the dorsal striatum. Life Sci 2004; 75: 633-638.
    • (2004) Life Sci , vol.75 , pp. 633-638
    • Guimaraes, V.M.1    Zuardi, A.W.2    Del Bel, E.A.3    Guimaraes, F.S.4
  • 20
    • 0032577340 scopus 로고    scopus 로고
    • Complex phar¬macology of natural cannabinoids: Evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain canna- binoid receptors
    • Petitet F, Jeantaud B, Reibaud M, Imperato A, Dubroeucq MC. Complex phar¬macology of natural cannabinoids: Evidence for partial agonist activity of delta9-tetrahydrocannabinol and antagonist activity of cannabidiol on rat brain canna- binoid receptors. Life Sci 1998; 63: PL1-PL6.
    • (1998) Life Sci , vol.63 , pp. PL1-PL6
    • Petitet, F.1    Jeantaud, B.2    Reibaud, M.3    Imperato, A.4    Dubroeucq, M.C.5
  • 21
    • 0022414990 scopus 로고
    • The func¬tional state of the dopamine receptor in the anterior pituitary is in the high- affinity form
    • George SR, Watanabe M, Di Paolo T, Falardeau P, Labrie F, Seeman P. The func¬tional state of the dopamine receptor in the anterior pituitary is in the high- affinity form. Endocrinology 1985; 117: 690-697.
    • (1985) Endocrinology , vol.117 , pp. 690-697
    • George, S.R.1    Watanabe, M.2    Di Paolo, T.3    Falardeau, P.4    Labrie, F.5    Seeman, P.6
  • 22
    • 0021239345 scopus 로고
    • Dopaminergic inhibition of adenylate cyclase correlates with high affinity agonist binding to anterior pituitary D2 dopamine receptors
    • McDonald WM, Sibley DR, Kilpatrick BF, Caron MG. Dopaminergic inhibition of adenylate cyclase correlates with high affinity agonist binding to anterior pituitary D2 dopamine receptors. Mol Cell Endocrinol 1984; 36: 201-209.
    • (1984) Mol Cell Endocrinol , vol.36 , pp. 201-209
    • McDonald, W.M.1    Sibley, D.R.2    Kilpatrick, B.F.3    Caron, M.G.4
  • 23
    • 0037255987 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of cannabinoids
    • Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet 2003; 42: 327-360.
    • (2003) Clin Pharmacokinet , vol.42 , pp. 327-360
    • Grotenhermen, F.1
  • 24
    • 40849137554 scopus 로고    scopus 로고
    • Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 hetero- mers. A combined neurochemical and behavioral analysis
    • Marcellino D, Carriba P, Filip M, Borgkvist A, Frankowska M, Bellido I. Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 hetero- mers. A combined neurochemical and behavioral analysis. Neuropharmacology 2008; 54: 815-823.
    • (2008) Neuropharmacology , vol.54 , pp. 815-823
    • Marcellino, D.1    Carriba, P.2    Filip, M.3    Borgkvist, A.4    Frankowska, M.5    Bellido, I.6
  • 25
    • 58149096475 scopus 로고    scopus 로고
    • Looking for the role of cannabinoid receptor heteromers in striatal function
    • Ferre S, Goldberg SR, Lluis C, Franco R. Looking for the role of cannabinoid receptor heteromers in striatal function. Neuropharmacology 2009; 56(Suppl 1): 226-234.
    • (2009) Neuropharmacology , vol.56 , pp. 226-234
    • Ferre, S.1    Goldberg, S.R.2    Lluis, C.3    Franco, R.4
  • 26
    • 84890068169 scopus 로고    scopus 로고
    • L-DOPA- treatment in primates disrupts the expression of A(2A) adenosine-CB(1) canna- binoid-D(2) dopamine receptor heteromers in the caudate nucleus
    • Bonaventura J, Rico AJ, Moreno E, Sierra S, Sanchez M, Luquin N et al. L-DOPA- treatment in primates disrupts the expression of A(2A) adenosine-CB(1) canna- binoid-D(2) dopamine receptor heteromers in the caudate nucleus. Neuro¬pharmacology 2014; 79: 90-100. 
    • (2014) Neuro¬pharmacology , vol.79 , pp. 90-100
    • Bonaventura, J.1    Rico, A.J.2    Moreno, E.3    Sierra, S.4    Sanchez, M.5    Luquin, N.6
  • 28
    • 84924993304 scopus 로고    scopus 로고
    • Dopamine super¬sensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia
    • Takase M, Kanahara N, Oda Y, Kimura H, Watanabe H, lyo M. Dopamine super¬sensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia. J Psychopharmacol 2015; 29: 383-389.
    • (2015) J Psychopharmacol , vol.29 , pp. 383-389
    • Takase, M.1    Kanahara, N.2    Oda, Y.3    Kimura, H.4    Watanabe, H.5    Lyo, M.6
  • 29
    • 43749124214 scopus 로고    scopus 로고
    • Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis
    • Morgan CJ, Curran HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry 2008; 192: 306-307.
    • (2008) Br J Psychiatry , vol.192 , pp. 306-307
    • Morgan, C.J.1    Curran, H.V.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.